Watch out Amgen and Teva, Eli Lilly got its green light for a rival CGRP migraine drug — and they’re coming after you
Eli Lilly has just scored the third FDA OK for a CGRP migraine drug, and now the pharma giant is setting out to leapfrog the pioneers who made it to market first.
The agency came through with the formal approval of Emgality (galcanezumab) on Thursday night, setting the stage for an ambitious and aggressive marketing engine to get revved up for a tire-burning late start.
“We certainly don’t think it’s a me-too situation,” says Wei-Li Shao, vice president of the neuroscience business at Eli Lilly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
